Home
Issues
Aim and Scope
Open Access
Editorial Board
Indexing
Why publish with us
Contact Us
Instructions to Authors (PDF)
Manuscript Types
Manuscript Formatting
How to submit
Preprints
Special publications & Reprints
Authorship & COI
Principles of Transparency Checklist
Data Policies
Publication Ethics and Publication Malpractice Statement
Crossmark
Supporting Diversity
Antibiotic therapy in severe COVID-19 between march 2020 and july 2022 and correlations with outcome in an intensive care unit in central Italy
1
University of Molise Department of Medicine and Health Sciences "Vincenzo Tiberio", University of Molise, Italy; School of Specialization in Hygiene and Preventive Medicine, University of Molise, Italy; Regional Health Agency of Molise region, Italy Italy
2
University of Molise
3
University of Molise School of Specialization in Hygiene and Preventive Medicine, University of Molise, Italy Italy
4
University of Molise Department of Medicine and Health Sciences "Vincenzo Tiberio", University of Molise, Italy Italy
Publication date: 2023-04-26
Popul. Med. 2023;5(Supplement):A535
ABSTRACT
Background and Objective:
Covid-19 can evolve into severe clinical manifestations requiring hospitalization in intensive care unit (ICU) where antibiotic therapy is extensively undertaken. Antimicrobials use was evaluated in relation to the outcomes (transfer in other wards/death) in COVID-19 patients in ICU between May 2020-July 2022 in Molise region, central Italy.
Methods:
Data were obtained from clinical records and internal ward software. A descriptive and univariate analysis was performed through SPSS v28.0 setting p2 antibiotics, and a significant relation with outcome was observed, as 86% and 98% deaths occurred among who took ≤2 and >2 antibiotics, respectively. Further differences were found between outcome and treatment with azithromycin, meropenem, ceftaroline, linezolid and teicoplanin. Polypharmacotherapy with ≥3 antibiotics was more common in male patients (81.3% vs 18.7%), while no differences with respect of age
Covid-19 can evolve into severe clinical manifestations requiring hospitalization in intensive care unit (ICU) where antibiotic therapy is extensively undertaken. Antimicrobials use was evaluated in relation to the outcomes (transfer in other wards/death) in COVID-19 patients in ICU between May 2020-July 2022 in Molise region, central Italy.
Methods:
Data were obtained from clinical records and internal ward software. A descriptive and univariate analysis was performed through SPSS v28.0 setting p2 antibiotics, and a significant relation with outcome was observed, as 86% and 98% deaths occurred among who took ≤2 and >2 antibiotics, respectively. Further differences were found between outcome and treatment with azithromycin, meropenem, ceftaroline, linezolid and teicoplanin. Polypharmacotherapy with ≥3 antibiotics was more common in male patients (81.3% vs 18.7%), while no differences with respect of age
| ISSN: | 2654-1459 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
